X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Insider Sells $13,121.55 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) insider Mark Baldry sold 29,159 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $13,121.55. Following the completion of the transaction, the insider now directly owns 94,123 shares in the company, valued at approximately $42,355.35. This represents a 23.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $0.74 on Thursday. X4 Pharmaceuticals, Inc. has a 1 year low of $0.26 and a 1 year high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The business has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.61. The company has a market capitalization of $125.39 million, a P/E ratio of -8.17 and a beta of 0.14.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $30,000. XTX Topco Ltd lifted its stake in shares of X4 Pharmaceuticals by 41.7% during the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after buying an additional 46,397 shares in the last quarter. SG Americas Securities LLC bought a new position in X4 Pharmaceuticals in the 3rd quarter worth approximately $37,000. Finally, Point72 Asset Management L.P. boosted its holdings in X4 Pharmaceuticals by 15.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after buying an additional 81,968 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on XFOR shares. HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th. Stifel Nicolaus lowered their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.